Repligen (RGEN) analyst forecast and price target
Analyst forecast
Consensus of 22 analyst ratings
Based on 4 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Barclays | Maintained | Overweight | $225.00 from $175.00 | Oct 7, 2026 |
| UBS | Maintained | Buy | $225.00 from $195.00 | Sep 9, 2026 |
| Wells Fargo | Maintained | Overweight | $185.00 from $180.00 | Jul 30, 2026 |
| JP Morgan | Maintained | Overweight | $175.00 from $165.00 | Jul 29, 2026 |
| Benchmark | Upgraded | Hold → Buy | $185.00 | Jul 7, 2026 |
| Evercore ISI Group | Maintained | Outperform | $160.00 from $150.00 | Jul 6, 2026 |
| HSBC | Maintained | Buy | $150.00 from $170.00 | Jun 3, 2026 |
| Wolfe Research | Initiated Coverage | Outperform | $145.00 | Jun 2, 2026 |
| RBC Capital | Maintained | Outperform | $160.00 | May 15, 2026 |
| Barclays | Maintained | Overweight | $160.00 from $145.00 | May 6, 2026 |
| JP Morgan | Maintained | Overweight | $165.00 from $180.00 | May 6, 2026 |
| Canaccord Genuity | Maintained | Hold | $145.00 from $165.00 | Apr 20, 2026 |
| Roth Capital | Initiated Coverage | Buy | $160.00 | Apr 17, 2026 |
| Barclays | Maintained | Overweight | $145.00 from $175.00 | Apr 14, 2026 |
| Evercore ISI Group | Maintained | Outperform | $140.00 from $170.00 | Apr 6, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $208.00 from $180.00 | Mar 23, 2026 |
| Evercore ISI Group | Maintained | Outperform | $170.00 from $180.00 | Feb 25, 2026 |
| Wells Fargo | Maintained | Overweight | $180.00 from $190.00 | Feb 25, 2026 |
| Barclays | Maintained | Overweight | $175.00 from $200.00 | Feb 25, 2026 |
| UBS | Maintained | Buy | $195.00 from $200.00 | Feb 25, 2026 |
Frequently asked questions
What is the price target for RGEN stock?
The average 12-month analyst price target for Repligen (RGEN) is $202.50, with a high estimate of $225.00 and a low of $175.00, across 4 analysts.
Is RGEN a buy, sell, or hold?
Analysts covering Repligen currently average a Buy rating: 17 buy, 4 hold and 1 sell, from 22 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for RGEN?
The average price target of $202.50 implies 9.95% upside from the last price of $184.17.
What is the latest analyst rating on RGEN?
On Oct 7, 2026, Barclays maintained Repligen at Overweight with a price target of $225.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.